comparemela.com

Latest Breaking News On - Acurx pharmaceuticals - Page 15 : comparemela.com

Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C difficile Infection

Based on observed aggregate blinded data the Company has determined that both treatments, ibezapolstat and the control antibiotic vancomycin, have performed as.

United statesDavidp luciRobertj delucciaData monitoring committeeInfectious diseases society of americaSociety for healthcare epidemiology of americaTrial oversight committeeDrug administrationPrnewswire acurx pharmaceuticals incCompany annual report on formAcurx pharmaceuticalsExchange commissionAcurx pharmaceuticals incClinical cureFast track designatedIndependent data monitoring committee

Acurx Pharma Discontinues Phase 2b Trial For Ibezapolstat To Treat C Difficile Infection

Biopharmaceutical company Acurx Pharmaceuticals, Inc. (ACXP) announced Monday that the Company has discontinued the Phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat, for the treatment of patients with Clostridioides difficile infection (CDI) due to success.

Data monitoring committeeAcurx pharmaceuticals incAcurx pharmaceuticalsIndependent data monitoring committeeFast track designatedAcurx pharmaClostridioides difficile infection

Will novel antibiotic become front-line for C difficile?

Will novel antibiotic become front-line for C difficile?
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

David luciDrug administrationAcurx pharmaceuticals incAcurx pharmaceuticalsChief executive

Acurx Pharmaceuticals, Inc (NASDAQ:ACXP) Short Interest Update

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Free Report) saw a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 6,700 shares, a drop of 51.1% from the August 31st total of 13,700 shares. Based on an average daily volume of 35,000 shares, the days-to-cover ratio […]

Acurx pharmaceuticals incAcurx pharmaceuticalsBlackrock incOsaic holdings incAcurx pharmaceuticals price performanceNews ratings for acurx pharmaceuticals dailyGlobal capitalGet free reportAcurx pharmaceuticals dailyNasdaq acxp

Acurx Pharmaceuticals, Inc (NASDAQ:ACXP) Sees Large Growth in Short Interest

Acurx Pharmaceuticals, Inc (NASDAQ:ACXP) Sees Large Growth in Short Interest
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Blackrock incInstitutional investors weigh in on acurx pharmaceuticalsAcurx pharmaceuticalsNews ratings for acurx pharmaceuticals dailyOsaic holdings incAcurx pharmaceuticals tradingGlobal capitalAcurx pharmaceuticals incAcurx pharmaceuticals company profileGet free reportAcurx pharmaceuticals daily

vimarsana © 2020. All Rights Reserved.